←
Nat Lester-Coll, MD7,029 posts
Nat Lester-Coll, MD avatar✓

Nat Lester-Coll, MD ✓

@DrLesterColl

Chair, Radiation Oncology, University of Vermont Health

◷ Joined January 2014▧ 1,369 Photos and videos
Nat Lester-Coll, MD avatar
Nat Lester-Coll, MD@DrLesterColl·Nov 12

Outlook down since 1 PM, expected “impacted” through the night Tomorrow's inbox: 300 emails, 3 that matter, and 40 reply-alls asking if anyone else's Outlook is down

Nat Lester-Coll, MD avatar
Nat Lester-Coll, MD@DrLesterColl·Nov 8

Target-trial emulation is still observational research. Treatment selection isn't random. Same core concern as other observational comparisons: unmeasured confounding, particularly confounding by indication. Better design helps, but doesn't replace randomization.

Nat Lester-Coll, MD avatar
Nat Lester-Coll, MD@DrLesterColl·Oct 27

Great breakdown👇 Clean randomized signal for pembro + MDT in oligometastatic RCC: RFS 11 → 25.4 mo (HR 0.47), 72% got SABR Next Q: patterns of recurrence after MDT ± pembro #radonc #ESMO26

Post attachment
Nat Lester-Coll, MD avatar
Nat Lester-Coll, MD@DrLesterColl·Oct 26

Honored to be elected to the @nnecos_oncology Board. NNECOS brings together oncology across ME, NH, and VT & gives our trainees a real regional stage. Looking forward to the work ahead with colleagues across the region.

Post attachmentPost attachment
Nat Lester-Coll, MD avatar
Nat Lester-Coll, MD@DrLesterColl·Sep 29

Grateful to organizers for PRO 11 @ #ASTRO26: Trial design keeps getting more complicated. Ph II data, de-escalation/omission studies, new tech routinely reported as practice-changing. Outstanding talks on how to read that evidence and which results should change practice!

Post attachment
Nat Lester-Coll, MD avatar
Nat Lester-Coll, MD@DrLesterColl·Sep 29

#ASTRO26 climate change, IT risk, and other system shocks make this more relevant every year. The real value here was in the stories: lessons for prevention and prep, and what we can actually do to safeguard RT when the next disruption hits. Thank you to this panel!

Post attachmentPost attachmentPost attachmentPost attachment
Jeff Ryckman avatar
⟳ Nat Lester-Coll, MD retweeted
Jeff Ryckman@jryckman3·Sep 28

Long-term PACE-A data at #ASTRO26 (van As LBA32, Yasar LBA10): the first randomized comparison of prostatectomy vs SBRT, 36.25 Gy in 5 fractions. These are contemporary surgical data: all prostatectomies were laparoscopic, 84% robotic. Using ≥1 pad/day, RP vs SBRT: • 2 years: 50% vs 7% • 5 years: 48% vs 8% Sexual function at 5 years: • EPIC sexual domain: 62→17 after RP vs 79→58 after SBRT • Median IIEF-5: 5 vs 19 Important caveats: as-treated analysis, approximately 60% PRO completion at 5 years, baseline sexual function imbalance, and enrollment of 123 of a planned 234 patients. Biochemical control looks similar through 8 years, but 13 events cannot establish equivalence. For shared decision-making, these are numbers I’d want patients to see. Every patient considering prostatectomy should have the opportunity to meet with a radiation oncologist before choosing treatment. #RadOnc #PCSM

Post attachment